Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have voluntarily agreed to take part and have signed an approved consent form.
- People aged between 18 and 80 years old.
- People who have a severe nerve cut (classified as Sunderland's 4th or 5th degree) in the arm or hand that has caused loss of nerve function and requires surgery to treat.
Who may not be able to join:
- People whose nerve repair surgery would happen more than 48 hours after the nerve was cut.
- People whose nerve repair would require using a piece of nerve taken from elsewhere in the body, a donor nerve, or a tube-like device to bridge the nerve gap.
- People with more than one cut nerve, unless all of the injured nerves can be repaired by directly rejoining the nerve ends (confirm with trial site).
- People who, in the opinion of the trial doctor, are unlikely to show meaningful recovery within a reasonable timeframe due to significant muscle wasting or other serious health conditions.
- People whose injury was the result of a suicide attempt or self-harm.
- People who have a documented history or signs of conditions where the study treatment might not be beneficial, such as diseases affecting the muscles or nervous system throughout the body, or who are on treatments known to affect nerve or blood vessel growth.
- People with a known allergy to polyethylene glycol (PEG) or medical-grade silicone.
- People who are pregnant or breastfeeding.
- People who are currently enrolled in another clinical trial, or who have taken part in one within the past 30 days before screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Seth Schulman, MD, Neuraptive Therapeutics Inc.
Phone: 215-206-9504
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain); Safety - Columbia-Suicide Severity Rating Scale
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.